Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Adaptimmune Therapeutics PLC (ADAP : NSDQ)

• Company Description    Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. Number of Employees: 494

• Price / Volume Information    Yesterday's Closing Price: $1.64 Daily Weekly Monthly 20 Day Moving Average: 689,837 shares Shares Outstanding: 161.87 (millions) Market Capitalization: $265.46 (millions) Beta: 2.07 52 Week High: $6.86 52 Week Low: $1.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.23% -4.99% 12 Week -39.03% -31.48% Year To Date -56.27% -46.57%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 JUBILEE AVENUE MILTON PARK - ABINGDON,X0 OX14 4RX GBR ph: 44-12-3543-0000 fax: 44-12-3543-0001 ir@adaptimmune.com http://www.adaptimmune.com

• General Corporate Information    Officers Adrian Rawcliffe - Chief Executive Officer and Director David M. Mott - Chairman Gavin Wood - Chief Financial Officer Lawrence M. Alleva - Director Ali Behbahani - Director Peer Information Adaptimmune Therapeutics PLC (CORR.) Adaptimmune Therapeutics PLC (RSPI) Adaptimmune Therapeutics PLC (CGXP) Adaptimmune Therapeutics PLC (BGEN) Adaptimmune Therapeutics PLC (GTBP) Adaptimmune Therapeutics PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00653A107 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 161.87 Most Recent Split Date: (:1) Beta: 2.07 Market Capitalization: $265.46 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.18 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.58 Price/Cash Flow: - Price / Sales: 28.57 EPS Growth vs. Year Ago Period: -33.33% vs. Previous Quarter: -28.00% Sales Growth vs. Year Ago Period: 723.73% vs. Previous Quarter: 152.29% ROE 03/31/22 - -76.84 12/31/21 - -61.15 09/30/21 - -53.31 ROA 03/31/22 - -41.79 12/31/21 - -38.93 09/30/21 - -38.81 Current Ratio 03/31/22 - 5.43 12/31/21 - 6.64 09/30/21 - 7.30 Quick Ratio 03/31/22 - 5.43 12/31/21 - 6.64 09/30/21 - 7.30 Operating Margin 03/31/22 - -1,836.31 12/31/21 - -2,571.00 09/30/21 - -2,499.92 Net Margin 03/31/22 - -1,836.31 12/31/21 - -2,571.00 09/30/21 - -2,499.92 Pre-Tax Margin 03/31/22 - -1,824.17 12/31/21 - -2,558.12 09/30/21 - -2,489.75 Book Value 03/31/22 - 1.04 12/31/21 - 1.32 09/30/21 - 1.54 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©